Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regorafenib + ECT204 T cells
- Development stage
- Unknown
- Lead developer
- Eureka Therapeutics
- Modality
- Small Molecules, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Oral, Intravenous
01
Overview
This is an investigational **combination therapy** consisting of **regorafenib**, a small molecule multi-kinase inhibitor, and **ECT204 T cells**, a genetically-engineered, autologous T cell therapy utilizing the ARTEMIS platform. ECT204 T cells are modified to express a proprietary anti-glypican 3 (GPC3) ARTEMIS T cell receptor (AbTCR), enabling targeting and destruction of GPC3-expressing tumor cells in hepatocellular carcinoma (HCC). Regorafenib is administered as a pre-treatment before ECT204 infusion and may serve to modulate the tumor microenvironment and enhance immunotherapeutic efficacy. This combination is currently under Phase 2 clinical investigation in adults with advanced GPC3-positive HCC who have failed at least two prior systemic therapies[1][5][9].
- Brand names
- STIVARGA
- Other names
- ARTEMIS ECT204 T cellsanti-GPC3 ARTEMIS T cellsanti-GPC-3 ARTEMIS T cellsanti-GPC 3 ARTEMIS T cells
02
Targets
KCNH2 (Voltage-gated potassium channel subfamily H member 2)NTRK1 (Tropomyosin-related receptor kinase A)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)RAF1 (c-Raf-1 (Y340D/Y341D))ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)TEK (Tie2)VEGFR-1 (Vascular endothelial growth factor receptor 1)GPC3 (Glypican-3)VEGFR3 (Vascular endothelial growth factor receptor 3)BRAF V600EFGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)EPHA2 (Ephrin type-A receptor 2)DDR2 (Discoidin domain receptor tyrosine kinase 2)
Beyond the preview
Go deeper on regorafenib + ECT204 T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regorafenib + ECT204 T cells.